Acromegaly
Conditions
Interventions
Duration 1 year Subject acromegaly Drug therapy
Sponsors
Osaka University Graduate School of Medicine Department of Metabolic Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient who is diagnosed acromegaly using "The clinical guideline of diagnosis and treatment in acromegaly" made by the research group of hypothalamohypophysial disease of Ministry of Health, Labour and Welfare in Japan Patient who has poor growth hormone control
Exclusion criteria
Exclusion criteria: Patient whom octoreotide LAR is contraindicated for Patient whose serum bilirubin or creatinine concentration is more than three fold above its upper normal range Patient whose serum AST or ALT concentration is more than five fold above its upper normal range Patient who has malignancy Patient who has received radiation therapy for pituitary within 10 years Patient who is unsuitable for this study (Judged by a doctor)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Growth hormone, Insulin-like growth factor-1 | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL, clinical symptom, complication | — |
Countries
Japan
Contacts
Public ContactMichio Otsuki
Osaka University Graduate School of Medicine Department of Metabolic Medicine
Outcome results
None listed